<DOC>
	<DOCNO>NCT02289599</DOCNO>
	<brief_summary>This study single-center , single dose , randomize , double-blind , placebo-controlled study healthy Japanese male subject . The study consist 2 part : Part A ( young subject ) Part B ( elderly subject ) . In Part A sequential cohort subject treat single ascending dos E2307 . The maximum tolerated dose ( MTD ) determine Part A . Part B initiate Part A complete . In Part B one cohort healthy elderly subject treat single dose E2307 one dose level MTD . In part A , total 56 subject enrol 7 cohort sequentially randomize 3:1 receive either E2307 ( 1 mg , 3 mg , 10 mg , 30 mg , 100 mg , 200 mg , 300 mg ) placebo . In part B , total 8 subject randomize , 6 subject single dose E2307 2 subject placebo .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics E2307 Healthy Young Elderly Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Parts A B 1 . Provide write informed consent 2 . Willing able comply aspect protocol Part A : Young cohort 3 . Nonsmoking , male subject age &gt; =20 year less 55 year old time inform consent Part B : Elderly Cohort 4 . Nonsmoking , male subject age &gt; =65 year less 85 year old time inform consent Subjects meet follow criterion exclude study : 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week dose 2 . Any history abdominal surgery may affect PK profile E2307 ( eg . hepatectomy , nephrectomy , digestive organ resection ) 3 . Known history clinically significant drug allergy ( Screening )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy Japanese Subjects</keyword>
	<keyword>E2307</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>